PJP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PJ

Volume

27.44K

Loading chart

PJ

PJPInvesco Pharmaceuticals ETF

PJP

Pay with—

Available Balance0.00

PJ

AUM

N/A

Volume

27.44K

Yield

0.97%

Chart Earnings News About Dividends Insider Filings

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJPVanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%).The Motley Fool · Oct 3, 2026

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?The Invesco Pharmaceuticals ETF (PJP) is a passively managed fund tracking the Dynamic Pharmaceutical Intellidex Index with $541.13 million in assets. It offers broad exposure to U.S. pharmaceutical companies with a 0.57% expense ratio and 0.82% dividend yield. The ETF has gained 24.96% year-to-date and 41.74% over the past year but carries higher risk with a beta of 0.45 and 16.02% standard deviation. It holds 32 stocks with top positions in Abbott Laboratories, Amgen, and Abbvie, and carries a Zacks ETF Rank of 3 (Hold).Zacks Investment Research · Sep 3, 2026

Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with a lower 0.35% expense ratio and concentrated biotech focus, versus Invesco Pharmaceuticals ETF (PJP) with higher dividend yield and broader pharma exposure. Despite PJP's superior 5-year performance and lower volatility, the article concludes BBH is the better buy based on recent outperformance, though both funds offer targeted healthcare sector exposure with different risk-return profiles.The Motley Fool · Aug 28, 2026

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?The Invesco Pharmaceuticals ETF (PJP) offers concentrated exposure to 29 pharma giants with better historical returns and lower volatility, while the Invesco Nasdaq Biotechnology ETF (IBBQ) provides broader diversification across 251 holdings at a lower expense ratio of 0.19% versus 0.57%. Despite IBBQ's cost advantage, PJP is recommended as the better buy due to its significantly larger asset base ($512.6M vs $81M), which addresses liquidity concerns.The Motley Fool · Aug 19, 2026

As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and Invesco Pharmaceuticals ETF (PJP). VHT offers broader sector exposure with 411 holdings, a lower expense ratio of 0.09%, and higher dividend yield of 1.60%. PJP focuses narrowly on 29 pharmaceutical stocks with a 0.57% expense ratio and 0.90% yield. Despite VHT's cost advantages, PJP has significantly outperformed over 3 and 5-year periods (17.3% and 9.1% returns respectively), leading the author to recommend PJP as the better buy for 2026.The Motley Fool · Jul 22, 2026

Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?The article compares two healthcare ETFs: Invesco Pharmaceuticals ETF (PJP), which focuses on concentrated U.S. pharma exposure with 29 holdings, and iShares Global Healthcare ETF (IXJ), which offers diversified global healthcare with 110 holdings. PJP delivered superior 1-year returns of 44.90% versus IXJ's 18.20%, though IXJ has a lower expense ratio (0.40% vs 0.57%) and higher dividend yield (1.50% vs 0.90%). The article recommends PJP for investors seeking healthcare exposure due to its stronger performance across most timeframes.The Motley Fool · Jul 20, 2026

Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?The article compares two healthcare-focused ETFs: Invesco Pharmaceuticals ETF (PJP) and First Trust NYSE Arca Biotechnology Index Fund (FBT). PJP focuses on established pharmaceutical companies with lower volatility and dividend income, while FBT targets high-growth biotech stocks with greater exposure to small and mid-cap companies. Despite FBT's stronger 10-year performance, PJP is recommended as the better buy due to its superior 5-year returns, lower volatility, dividend yield, and more stable risk profile.The Motley Fool · Jul 8, 2026

Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?VanEck Pharmaceutical ETF (PPH) offers a lower expense ratio (0.36%) and higher dividend yield (2.00%), making it ideal for income-focused investors, while Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (49.90% vs 27.10%) but has higher fees (0.57%). PPH provides global exposure with better 5-year performance, while PJP focuses exclusively on U.S. stocks and benefits from sector momentum like the GLP-1 weight loss trend.The Motley Fool · Jul 4, 2026

Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer TrialPfizer announced that its Braftovi regimen demonstrated statistically significant improvements in progression-free survival and objective response rates for metastatic colorectal cancer patients with BRAF V600E mutation in the Phase 3 BREAKWATER trial, outperforming standard chemotherapy treatments. The stock is trading near 52-week highs with mixed technical momentum.Benzinga · Feb 17, 2026

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?Smart Beta ETF report for PJPZacks Investment Research · Jun 28, 2024

to start trading

PJ

PJPInvesco Pharmaceuticals ETF

PJP

Pay with—

Available Balance0.00

Your PositionYou don't own any PJP yet.

Related Tickers

Earnings

Dividends

Last · Sep 21Quarterly

Amount$0.30

Yield0.91%

Annual$1.13